Zafnil

Uses

Zukast is used for the treatment of asthma.

Zafnil is also used to associated treatment for these conditions: Asthma, Chronic Urticaria

How Zafnil works

Zafnil is a selective and competitive receptor antagonist of leukotriene D4 and E4 (LTD₄ and LTE4), components of slow-reacting substance of anaphylaxis (SRSA). Cysteinyl leukotriene production and receptor occupation have been correlated with the pathophysiology of asthma, including airway edema, smooth muscle constriction, and altered cellular activity associated with the inflammatory process, which contribute to the signs and symptoms of asthma.

Dosage

Zafnil dosage

Zafnil should be taken continuously. Children under 7 years of age: There is no clinical experience of the use of Zafnil in children under 7 years of age until safety information is available.Children over 7 years through 11 years of age: The recommended dose of Zafnil in this age group is 10 mg twice daily.Adult and children aged 12 years and over: The dosage is one 20 mg tablet twice daily. This dosage should not be exceeded. Higher doses may be associated with elevations of one or more liver enzymes consistent with hepatotoxicity. As food may reduce the bioavailability of Zafnil, Zafnil should not be taken with mealsElderly: The clearance of Zafnil is significantly reduced in elderly patients (over 65 years old), and Cmax and AUC are approximately double than those of younger adults. However, accumulation of Zafnil is not greater than that seen in multiple dose trials conducted in adult subjects with asthma and the consequences of the altered kinetic in the elderly are unknown. Clinical experience with Zafnil in the elderly (over 65 years) is limited and caution is recommended until further information is available.Renal impairment: No dosage adjustment is necessary in patients with mild renal impairment.

Side Effects

Effect on ability to drive or operate machinery: There is no evidence that Zafnil affects the ability to drive and use machinery. Administration of Zafnil in clinical trials against placebo has been associated with headache (9.9% vs. 9.0%) or gastrointestinal disturbance (nausea 2.6% vs. 2.2%, vomiting 1.2% vs. 1.0%, diarrhoea 2.3% vs. 1.8%, abdominal pain 1.6% vs. 1.2%). These symptoms are usually mild and do not necessitate withdrawal from therapy. During post-marketing experience, bruising, bleeding disorders, including menorrhagia (rare), thrombocytopaenia and agranulocytosis (very rare) have also been reported.Hypersensitivity reactions, including urticaria and angio-oedema have been reported. Rashes, including blistering, have also been reported. The above events have usually resolved during continued treatment or following cessation of therapy. Infrequently, elevated serum transaminase levels have been observed in clinical trials against placebo with Zafnil (increased AST 1.0% vs. 0.9%, increased AST 0.6% vs. 0.6%); at recommended doses the incidence was equivalent to placebo. Rarely the transaminase profile has been consistent with drug-induced hepatitis, which resolved following cessation of Zafnil therapy. During post-marketing experience there have been rare reports of hepatitis, with or without elevated bilirubin levels. These cases were usually reversible.In placebo controlled clinical trials, an increased incidence of infection has been observed in elderly patients given Zafnil (7.8% vs. 1.4%). Infections were usually mild, predominantly affecting the respiratory tract.

Toxicity

Side effects include rash and upset stomach.

Precaution

Zafnil should be taken regularly to achieve benefit, even during symptom free periods. Zafnil therapy should normally be continued during acute exacerbations of asthma. Zafnil does not allow a reduction in existing steroid treatment. As with inhaled steroids and hormones (disodium cromoglycate, nedocromil sodium), Zafnil is not indicated for use in the reversal of bronchospasm in acute asthma attacks. Zafnil has not been evaluated in the treatment of labile (brittle) or unstable asthma.Cases of Churg Strauss syndrome have been reported in association with Zafnil usage. A causal relationship has neither been confirmed nor refuted. If a patient develops a Churg Strauss syndrome type illness, Zafnil should be stopped, a re-challenge test should not be performed and treatment should not be restarted.Elevations in serum transaminases can occur during treatment with Zafnil. These are usually asymptomatic and transient but could represent early evidence of hepatotoxicity.If clinical symptoms or signs suggestive of liver dysfunction occur (e.g., nausea, vomiting, right upper quadrant pain, fatigue, lethargy, flu-like symptoms, enlarged liver, pruritus and jaundice), the serum transaminases, in particular serum ALT, should be measured and the patient managed accordingly. A decision to discontinue Zafnil should be individualized to the patient’s condition, weighing the risk of hepatic dysfunction against the clinical benefit of Zafnil to the patient.

Interaction

Zafnil may be administered with other therapies routinely used in the management of asthma and allergy. Inhaled steroids, inhaled and oral bronchodilator therapy, antibiotics and antihistamines are examples of agents which have been co-administered with Zafnil without adverse interaction.Zafnil may be administered with oral contraceptives without adverse interaction. Co-administration with Warfarin results in an increase in maximum prothrombin time by approximately 35%. It is therefore recommended that if Zafnil is co-administered with Warfarin, prothrombin time should be closely monitored. The interaction is probably due to an inhibition by Zafnil of the cytochrome P450 2C9 enzyme system. In clinical trials co-administration with Theophylline resulted in decreased plasma levels of Zafnil, by approximately 30%, but with no effect on plasma Theophylline levels. However, during postmarketing surveillance, there have been rare cases of patients experiencing increased Theophylline levels when co-administered with Zafnil.Co-administration with Terfenadine resulted in a 54% decrease in AUC for Zafnil, but with no effect on plasma Terfenadine levels. Coadministration with Acetylsalicylic acid (650 mg four times a day) may result in increased plasma levels of Zafnil, by approximately 45%.Co-administration with Erythromycin will result in decreased plasma levels of Zafnil, by approximately 40%. The clearance of Zafnil in smokers may be increased by approximately 20%

Food Interaction

• Take on an empty stomach. Take at least 1 hour before or 2 hours after meals.

[Moderate] ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of zafirlukast.

In two separate studies, one using a high-fat and the other a high-protein meal, administration of zafirlukast with food reduced the mean bioavailability by approximately 40%.

MANAGEMENT: To ensure maximal oral absorption, zafirlukast should be administered at least 1 hour before or 2 hours after meals.

Zafnil Drug Interaction

Moderate: aspirin, montelukast, budesonide / formoterolMinor: escitalopramUnknown: fluticasone / salmeterol, diphenhydramine, ubiquinone, formoterol / mometasone, omega-3 polyunsaturated fatty acids, fluticasone nasal, pregabalin, albuterol, tiotropium, levothyroxine, albuterol, cyanocobalamin, ascorbic acid, ergocalciferol, cholecalciferol, cetirizine

Zafnil Disease Interaction

Major: liver disease

Volume of Distribution

• 70 L

Elimination Route

Rapidly absorbed following oral administration, reduced following a high-fat or high-protein meal.

Half Life

10 hours

Clearance

• apparent oral CL=20 L/h
• 11.4 L/h [7-11 yrs]
• 9.2 L/h [5-6 yrs]

Elimination Route

The most common metabolic products are hydroxylated metabolites which are excreted in the feces.

Pregnancy & Breastfeeding use

Pregnancy: The safety of Zafnil in human pregnancy has not been established. In animal studies, Zafnil did not have any apparent effect on fertility and did not appear to have any teratogenic or selective toxic effect on the foetus. The potential risks should be weighed against the benefits of continuing therapy during pregnancy and Zafnil should be used during pregnancy only if clearly needed.Lactation: Zafnil is excreted in human breast milk. Zafnil should not be administered to nursing mothers.

Contraindication

Zafnil should not be given to patients who have previously experienced hypersensitivity to the product or any of its ingredients. Zafnil is contraindicated in patients with a history of moderate or severe renal impairment. Zafnil is contraindicated in patients with hepatic impairment or cirrhosis; it has not been studied in patients with hepatitis or in long term studies of patients with cirrhosis. Zafnil is contraindicated in children under 7 years of age until safety information is available.

Storage Condition

Store between 20-25° C. Protect from light and moisture.

Innovators Monograph

You find simplified version here Zafnil